Monoamine and neuropeptide-related function: prospects for novel therapeutics of depression

References

• Kessler RC, McGonagle IKA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiany 51(1), 8–19 (1994).
   Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349(9064), 1498–1504 (1997).
   Google Scholar
• Glassman AH. Depression, cardiac death and the central nervous system. Neuropsychobiology37 (2), 80–83 (1998).
   PubMedGoogle Scholar
• Brown GK, Beck AT, Steer RA, Grisham JR. Risk factors for suicide in psychiatric out-patients: a 20-year prospective study. Consult. Orin. PTchol. 68(3), 371–377 (2000).
   Google Scholar
• Coryell W, Arndt S, Turvey C et al. Lithium and suicidal behavior in major affective disorder: a case- control study. Acta fisychiatc Land. 104(3), 193–197 (2001).
   Google Scholar
• Keck PE, Jr., Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility and suicidality in patients with schizophrenia. j Clin. Psychiatry 61 (Suppl. 3), 4–9 (2000).
   Google Scholar
• Meltzer HY. Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial. j Clin. Psychiatry 60\(Suppl. 12), 47–50 (1999).
   Google Scholar
• Vangala VR, Brown ES, Suppes T Clozapine associated with decreased suicidality in bipolar disorder: a case report. BipolarDisarl 1(2), 123–124 (1999).
   PubMedGoogle Scholar
• Banki CM. Prophylactic potential of selective re-uptake inhibitors in suicidal patients. mt. Clin. Rychophatmacol. 9\(Suppl. 4), 61–65 (1995).
   Google Scholar
• Carlsson A. A paradigm shift in brain research. Science 294(5544), 1021–1024 (2001).
   PubMed Web of Science ®Google Scholar
• •A nice combination of history on neuropharrnacology and exploration of mechanisms of action of antidepressant and other neuropharrnaceuticals through the eyes of a Nobel Prize winner.
   Google Scholar
• Cryan JF, Lucki I. Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. Pharmacol Exp. Ther. 295(3), 1120–1126 (2000).
   Google Scholar
• •A good article describing the forced swim test and the potential importance of the 5-HT2c receptor in antidepressant action.
   Google Scholar
• Spigset O. Adverse reactions of selective serotonin re-uptake inhibitors: reports froma spontaneous reporting system. Drug Sal 20(3), 277–287 (1999).
   PubMedGoogle Scholar
• Frye MA, Ketter TA, Altshuler LL et al Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. Affect. Dison-1. 48(2–3), 91–104 (1998).
   Google Scholar
• Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J. Clin. Psychiatry 60(2), 116–118 (1999).
   Google Scholar
• Weisler RII, Ahearn EP, Davidson JR, Wallace CD. Adjunctive use of olanzapine in mood disorders: five case reports. Ann. Clin. Psychiatry 9 (4), 259–262 (1997) .
   Google Scholar
• Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am. J. PTchiaby 158(1), 131–134 (2001).
   Google Scholar
• •An important pilot study for the treatment of refractory or treatment-resistant depression.
   Google Scholar
• Stoll AL, Haura G. Tranylcypromine plus risperidone for treatment-refractory major depression. .1. Gun. PTchopharmacol 20(4), 495–496 (2000).
   Google Scholar
• Holsboer E Prospects for antidepressant drug discovery. Biol. Psychol. 57(1-3), 47–65 (2001).
   Google Scholar
• Middlemiss DN, Gothert M, Schlicker E et al SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. Eur. j Pharmacol 375(1–3), 359–365 (1999).
   Google Scholar
• Casanovas JM, Lesourd M, Artigas E The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-0H-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain. BE J. Pharmacol 122(4), 733–741 (1997).
   Google Scholar
• Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch. Gen. PTchiatry54(7), 597–606 (1997).
   Google Scholar
• •A good review of intracellular mechanisms and new concepts regarding antidepressant action.
   Google Scholar
• Chamey D, Nestler EJ, Bunney BS (Eds). Neurobiology of Mental Illness. Oxford University Press, New York, USA (1999).
   Google Scholar
• •A good introduction to the biology of depression and other mental disorders.
   Google Scholar
• Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biol. PTchiatry48(8), 732–739 (2000).
   Google Scholar
• •A good review of intracellular mechanisms and new concepts regarding antidepressant action.
   Google Scholar
• Czeh B, Michaelis T, Watanabe T et al Stress-induced changes in cerebral metabolites, hippocampal volume and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc. Natl Acad. Li. USA 98(22), 12796–12801 (2001).
   Google Scholar
• ••A very interesting recent article regardingrelationship between stress and antidepressant action.
   Google Scholar
• Duman RS, Malberg J, Nakagawa S. Regulation of adult neurogenesis by psychotropic drugs and stress. J. Pharmacol Exp. Ther. 299(2), 401–407 (2001).
   Google Scholar
• •Good review regarding neurogenesis in relation to antidepressants.
   Google Scholar
• Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments.j Neurosci. 15(11), 7539–7547 (1995).
   PubMed Web of Science ®Google Scholar
• •A good article regarding antidepressants and netuptrophism.
   Google Scholar
• Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. I Neurosci. 16 (7), 2365–2372 (1996).
   Google Scholar
• Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem. Behav 56(1), 131–137 (1997).
   Google Scholar
• Bech P, Cialdella P, Haugh MC etal. Meta- analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. BE J. Rychiatry176, 421–428 (2000).
   Google Scholar
• Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int. Gun. Psychopharmacol 16(3), 169–178 (2001).
   Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin re-uptake inhibitors. Br. PTchiatry178,234–241 (2001).
   Google Scholar
• ••High quality and important meta-analysisindicating possible high remission rates with venlafaxine.
   Google Scholar
• Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in out-patients. Prog. Neuropsychopharmacol Biol Psychiatry 20(1), 57–71 (1996).
   PubMed Web of Science ®Google Scholar
• Storosum JG, Elferink AJ, van Zwieten BJ et al Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 11(2), 173–180 (2001).
   PubMedGoogle Scholar
• Mulrow CD, Williams JW, Jr., Chiquette E et al Efficacy of newer medications for treating depression in primary care patients. Am Med 108(1)54-64 (2000).
   Google Scholar
• Meyer JH, Kapur S, Eisfeld B et al The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)Flsetoperone PET imaging study. Ainj PTchiatry158(1), 78–85 (2001).
   Google Scholar
• Siever U. Antidepressant selection in the postgenomic era. Biol. Psychiatry 48(9), 875–877 (2000).
   PubMedGoogle Scholar
• Delgado PL, Miller HL, Salomon RM et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol. Psychiatry 46(2), 212–220 (1999).
   PubMedGoogle Scholar
• Ortiz J, Mocaer E, Artigas E Effects of the antidepressant drug tianeptine on plasma and platelet serotonin concentrations in the rat. Eur Phatmacol 199(3), 335–339 (1991).
   PubMedGoogle Scholar
• Wilde MI, Benfield P Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depression and coexisting anxiety and depression [published erratum appears in Drugs50(1), 156 (1995)1. Drugs 49(3), 411–439 (1995).
   Google Scholar
• Kelly JP, Leonard BE. The effect of tianeptine and sertraline in three animal models of depression. Neumphalmacology 33(8), 1011–1016 (1994).
   PubMedGoogle Scholar
• Pineyro G, Deveault L, de Montigny C, Blier P Effect of prolonged administration of tianeptine on 5-HT neurotransmission: an electrophysiological study in the rat hippocampus and dorsal raphe. Naunyn Schmiedebergs Arch. Pharmacol 351 (2), 119–125 (1995).
   Google Scholar
• Watanabe Y, Gould E, Daniels DC, Cameron H, McEwen BS. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur. Pharmacol 222(1), 157–162 (1992).
   Google Scholar
• Frankfurt M, McKittrick CR, McEwen BS, Luine VN. Tianeptine treatment induces regionally specific changes in monoamines. Brain Res. 696(1-2), 1–6 (1995).
   Google Scholar
• Castanon N, Konsman J-P, Medina C, Chauvet N, Dantzer R. Chronic treatment with the antidepressant tianeptine attenuates lioppolycaccharide-induced Fos expression in the rat paraventricular mucleus and HPA axis activation. Manuscript (2001).
   Google Scholar
• Maes M, Song C, Lin AH et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology20(4), 370–379 (1999).
   Google Scholar
• Schramm TM, Lawford. BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med Aust. 173(7), 359–361 (2000).
   Google Scholar
• Skolnick P, Legutko B, Li X, Bymaster FP. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res. 43(5), 411–423 (2001).
   Google Scholar
• Loo H, Saiz-Ruiz J, Costa e Silva J et al Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J. Affect. Disord 56(2–3), 109–118 (1999).
   Google Scholar
• Ginestet D. Efficacy of tianeptine in major depressive disorders with or without melancholia. Eur. Neuropsychopharmacol 7\(Suppl. 3), S341-345 (1997).
   Google Scholar
• Costa e Silva JA, Ruschel SI, Caetano D et al Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology35 (1), 24–29 (1997).
   Google Scholar
• Berman RM, Anand A, Cappiello A et al The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol. PTchiatry 45 (9), 1170–1177 (1999).
   PubMedGoogle Scholar
• Pacher P, Kohegyi E, Kecskemeti V, Furst S. Current trends in the development of new antidepressants. CI.117: Med. Chem. 8(2), 89–100 (2001).
   Google Scholar
• Stenfors C. AR-A000002, a novel 5-HT1B selective antagonist with antidepressant potential. Eur Neuropsychophalmacol 11\(Suppl. 3), S178 (2001).
   Google Scholar
• Meyer MD, Hancock AA, Tietje K etal. Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT uptake inhibiting and alpha2-antagonistic activities. Med Chem. 40(7), 1049–1062 (1997).
   Google Scholar
• Backus LI, Sharp T, Grahame-Smith DG. Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. BE J. Pharmacol 100(4), 793–9 (1990).
   Google Scholar
• Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry 46(9), 1181–1191 (1999).
   Google Scholar
• Mossner R, Daniel S, Albert D et al Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Aimuchem. Int. 36(3), 197–202 (2000).
   Google Scholar
• Mamounas LA, Altar CA, Blue ME, Kaplan DR, Tessarollo L, Lyons WE. BDNF promotes the regenerative sprouting but not survival, of injured serotonergic axons in the adult rat brain. J. Neurosci 20(2), 771–782 (2000).
   PubMed Web of Science ®Google Scholar
• Lyons WE, Mamounas LA, Ricaurte GA et al Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc. Natl Acad. Sci. USA 96(26), 15239–15244 (1999).
   Google Scholar
• Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol Exp. Ther. 292(1), 76–87 (2000).
   Google Scholar
• Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Frog. Brain. Res. 126,413–431 (2000).
   PubMed Web of Science ®Google Scholar
• Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53(4), 608–636 (1997).
   Google Scholar
• Dube S, Shelton RC, Sofia P et al. Olanzapine-fluoxetine combination in treatment-resistant depression, in Presented at American College of Psychopharmacology Annual Meeting. Hawaii, USA (2001).
   Google Scholar
• Marek GJ, Martin-Ruiz R, Abo A, Artigas Synergistic Antidepressant-like Action Between A highly Selective 5-HT2A Antagonist (M100907) and the SSRI Fluoxetine on DRL 72-S Behavior, in Presented at the Annual Meeting, American College of Neuropsychopharmacology. Hawaii, USA (2001).
   Google Scholar
• Ordway GA, Zhu M, Klimek V, Offord SJ. Downregulation of tyrosine hydroxylase in the rat locus coeruleus following chronic treatment with M100907. Soc. Neuroci. Abstr 23,1660 (1997).
   Google Scholar
• Hatanaka K, Yatsugi S, Yamaguchi T Effect of acute treatment with YM992 on extracellular noradrenaline levels in the rat frontal cortex. Eur. Pharmacol 395(1), 31–36 (2000).
   Google Scholar
• Takeuchi H, Yatsugi S, Hatanaka K et al. Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity. Eur j Pharmacol 329(1), 27–35 (1997).
   Google Scholar
• Pullar IA, Carney SL, Colvin EM, Lucaites VL, Nelson DL, Wedley S. LY-367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone. Eur. Pharmacol 407(1–2), 39–46 (2000).
   Google Scholar
• Scorza C, Silveira R, Nichols DE, Reyes- Parada M. Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action. Neumpharmacology38(7), 1055–1061 (1999).
   Google Scholar
• Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J. Gun. Psychiatry 59 (Suppl. 14), 11–14 (1998).
   Google Scholar
• Ressler KJ, Nemeroff CB. Role of noradrenaline in the pathophysiology and treatment of mood disorders. Biol. Psychiatry 46(9), 1219–1233 (1999).
   PubMed Web of Science ®Google Scholar
• Wong ML, Kling MA, Munson PJ et al Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl Acad. Sci. USA 97(1), 325–330 (2000).
   Google Scholar
• Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ. Bupropion in depression. I. Biochemical effects and clinical response. Arch. Gen. Psychiatry 45(2), 139–143 (1988).
   Google Scholar
• Dong J, Blier P. Modification of noradrenaline and serotonin but not dopamine, neurone firing by sustained bupropion treatment. Psychopharmacology oerl) 155(1), 52–57 (2001).
   PubMed Web of Science ®Google Scholar
• Rogoz Z, Skuza G, Dlaboga D, Maj J, Dziedzicka-Wasylewska M. Effect of repeated treatment with tianeptine and fluoxetine on the central alpha(1)-adrenergic system. Neuropharmacology 41(3), 360–368 (2001).
   Google Scholar
• Lambert G, Johansson M, Agren H, Friberg P Reduced brain noradrenaline and dopamine release in treatment- refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Azrh. Gen. Psychiatry57(8), 787–793 (2000).
   Google Scholar
• •Important pilot data from an invasive and daring study sampling directly from venous drainage of brain in depression.
   Google Scholar
• Miller HL, Delgado PL, Salomon RM et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch. Gen. Ptychiatry53(2), 117–128 (1996).
   Google Scholar
• •Important paper regarding catecholamine mechanisms in depression tested using a challenge method.
   Google Scholar
• Thomas DN, Nutt DJ, Holman RB. Effects of acute and chronic electroconvulsive shock on noradrenaline release in the rat hippocampus and frontal cortex. Brj Pharmacol 106(2), 430–434 (1992).
   PubMedGoogle Scholar
• Thomas DN, Nutt DJ, Holman RB. Sertraline, a selective serotonin re-uptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. J. Ptychopharmacol 12(4), 366–370 (1998).
   Google Scholar
• Anderson IM. SSRIs versus tricyclic antidepressants in depressed in-patients: a meta-analysis of efficacy and tolerability. Depress. Anxiety 7\(Suppl. 1), 11–17 (1998).
   Google Scholar
• Kasper S, el Giamal N, Hilger E. Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin. Pharmacother. 1(4), 771–782 (2000).
   Google Scholar
• Linner L, Endersz H, Ohman D, Bengtsson F, Schalling M, Svensson TH. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J. Phatmacol Exp. Ther. 297(2), 540–546 (2001).
   Google Scholar
• Gallen CC, Brown MT Reboxetine, placebo and paroxetine comparison in patients with major depressive disorder: A double-blind, placebo-and comparator-controlled study. Eur Neuropsychopharmacolll (Suppl. 3), S216 (2001).
   Google Scholar
• Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J. Gun. Rychiatry 60(6), 400–406 (1999).
   Google Scholar
• Such P Reboxetine versusvenlafaxine in severe depression. A multinational double-blind randomized trial. Eur Aiuropsychophalmacol 11\(Suppl. 3), S212 (2001).
   Google Scholar
• Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int. Gun. Psychopharmacol 14(2), 73–80 (1999).
   Google Scholar
• Keller M. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS). Gen. Hosp. fiychiatry23(1), 15–19 (2001).
   Google Scholar
• Ferguson J, Wesnes K, Barker KS, Schwartz G. Reboxetine effects on cognitive functioning in depressed patients. Eur. Neuropsychopharmacol 11\(Suppl. 3), S217 (2001).
   Google Scholar
• Lamont SR, Paulls A, Stewart CA. Repeated electroconvulsive stimulation but not antidepressant drugs, induces mossy fibre sprouting in the rat hippocampus. Brain Res. 893(1-2), 53–58 (2001).
   PubMedGoogle Scholar
• Goldberg JF, Burdick KE, Endick CJ. A Preliminary Randomized Trial of Pramixpexole vs. Placebo Plus Mood Stabilizers in Bipolar Depression, in Presented at the Annual Meeting, American College of Neuropsychopharmacology. Hawaii, USA (2001).
   Google Scholar
• DeBattista C, Solvason FIB, Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin re-uptake inhibitor in the treatment of depression. J. Gun. Psychopharmacol 20(2), 274–275 (2000).
   Google Scholar
• Sporn J, Ghaemi SN, Sambur MR et al Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Gun. Psychiatry12(3), 137–140 (2000).
   Google Scholar
• Morrow TJ. The pharmacoeconomics of venlafaxine in depression. Am J. Manag. Cam7 (11 Suppl.), S386-392 (2001).
   Google Scholar
• Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 19 (4), 355–363 (1980).
   Google Scholar
• Baraban JM, Aghajanian GK. Noradrenergic innervation of serotonergic neurons in the dorsal raphe: demonstration by electron microscopic autoradiography. Brain Res. 204(1), 1–11 (1981).
   Google Scholar
• Besson A, Haddjeri N, Blier P, de Montigny C. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur. Neuropsychopharmacol 10(3), 177–188 (2000).
   Google Scholar
• Laakmann G, Schuele C. Mirtazapine inhibits salivary cortisol concentrations in Healthy Controls and Depressed Patients, in 2001 Annual Meeting, American College on Neuropsychopharmacology, Hawaii, USA (2001).
   Google Scholar
• Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J. Clin.Ptychiatry 62 (Suppl. 4), 17–23; discussion 37–40 (2001).
   Google Scholar
• Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRTs?j Gun. Psychiatry 62 (5), 358–361 (2001).
   Google Scholar
• Fava M, Dunner DL, Greist JH et al Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. Ptychiatry62(6), 413–420 (2001).
   PubMedGoogle Scholar
• Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J. Clin. Ptychiatry60(1), 45–49 (1999).
   Google Scholar
• Pitsikas N. Duloxetine Eli Lilly & Co. Curr. Opin. Investzg Drugs1(1), 116–121 (2000).
   Google Scholar
• Chalon S, Granier L-A, Vandenhende F et al Duloxetine: Pharmacodynamic evidence in man of dual re-uptake inhibition. Eur. Neuropsychopharmaco1.11\(Suppl. 3), S211 (2001).
   Google Scholar
• Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Efficacy and safety of duloxetine in the treatment of major depression. Eur. Neuropsychopharmacol 11 (Suppl. 3), S212 (2001).
   Google Scholar
• Goldstein DJ, Lu Y, Detke M, Wiltse C, Mallinckrodt C, Demitrack MA. The New Balanced Dual 5-HT/NE Re-uptake Inhibitor Duloxetine: A Double-Blind Placebo-Controlled Clinical Trial, in Presented at the Annual Meeting of the American College of Neuropsychopharmacology. Hawaii, USA (2001).
   Google Scholar
• Detke M, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg QD is Efficacious in the Treatment of Depression, in Presented at the Annual Meeting, American College of Neuropsychopharmacology. Hawaii, USA (2001).
   Google Scholar
• Hokfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, Diez M. Neuropeptides-an overview. Neuropharmacology39(8), 1337–1356 (2000).
   PubMedGoogle Scholar
• •Examines the concepts of importance in neuropeptide research.
   Google Scholar
• Holsboer E The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 (5), 477–501 (2000).
   Google Scholar
• •A high quality review paper.
   Google Scholar
• Brunson KL, Eghbal-Ahmadi M, Bender R, Chen Y, Baram TZ. Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress. Proc. Natl Acad. Sc]. USA 98(15), 8856–8861 (2001).
   Google Scholar
• ••Important paper exploring the possibilitythat CRF itself may damage immature CNS circuits.
   Google Scholar
• Zobel AW, Nickel T, Kunzel HE et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.j Rychiatr Res. 34(3), 171–181 (2000).
   Google Scholar
• Stout SC, Mortas P, Owens MJ, Nemeroff CB, Moreau J. Increased corticotropin-releasing factor concentrations in the bed nucleus of the stria terminalis of anhedonic rats. Eur Pharmacol. 401(1), 39–46 (2000).
   PubMedGoogle Scholar
• Heuser I, Bissette G, Dettling M et al. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress. Anxiety 8(2), 71–79 (1998).
   PubMedGoogle Scholar
• Banki CM, Karmacsi L, Bissette G, Nemeroff CB. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychophannacol 2(2), 107–113 (1992).
   PubMedGoogle Scholar
• Belanoff JK, Flores BH, Kalezhan M, Sund B, F SA. Rapid reversal of psychotic depression using mifepristone. j Clin. Rychopharm. 21(5), 516–521 (2001).
   Google Scholar
• •Preliminary data on a new antiglucocorticoid strategy in depression.
   Google Scholar
• Holsboer E CRIIR1 Antagonists as Novel Treatment Strategies. CNS Spectrums 6(7), 590–594 (2001).
   Google Scholar
• Linthorst AC, Flachskamm C, Hopkins SJ et al Long-term intracerebroventricular infusion of corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral and cytokine responses to a systemic inflammatory challenge. J. Neurosci. 17(11), 4448–4460 (1997).
   PubMed Web of Science ®Google Scholar
• Habib KE, Weld IQ, Rice KC etal. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine and autonomic responses to stress in primates. Proc. Natl Acad. Sc]. USA 97(11), 6079–6084 (2000).
   Google Scholar
• Owens MJ, Nemeroff CB. Corticotropin-releasing factor antagonists in affective disorders. Expert Opin. Investig. Drugs 8(11), 1849–1858 (1999).
   Google Scholar
• •A good review paper.
   Google Scholar
• Owens MJ, Gutman DA. CRF-1 Receptor Antagonists: Long Term Treatment and Efficacy in Animal Models. Eur NeuropTchopharmacol 11 (Suppl. 3), S179 (2001).
   Google Scholar
• Rupniak NM. Evidence for antidepressant and anxiolytic activity of substance P (NK1 RECEPTOR) antagonists in preclinical assays, in Presented at the American College of Neuropsychopharmacology Annual Meeting. Hawaii, USA (2001).
   Google Scholar
• Kramer MS, Cutler N, Feighner J et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281(5383), 1640–1645 (1998).
   PubMed Web of Science ®Google Scholar
• ••A classic paper.
   Google Scholar
• Kramer MS, Ball WA, Reines SA. Replication of the Efficacy and Tolerability of Substance P Antagonists in Patients with Major Depression, in Presented at the Annual Meeting of the American College of Neuropsychopharmacology. Hawaii, USA (2001).
   Google Scholar
• Froger N, Gardier AM, Moratalla R et al 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knockout mice mimic antidepressant-induced desensitization. J. Neurosci. 21(20), 8188–8197 (2001).
   Google Scholar
• Feighner JP, Ehrensing RH, Kastin AJ et al. Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of out-patients with major depression. Int. Clin. Psychopharmacol 16(6), 345–352 (2001).
   Google Scholar
• •An intriguing new antidepressant to watch.
   Google Scholar
• Feighner JP, Sverdlov L, Nicolau G, Noble JE Cluster analysis of clinical data to identify subtypes within a study population following treatment with a new pentapeptide antidepressant. Int. J. Neumpsychopharmacol 3(3), 237–242 (2000).
   Google Scholar
• Feighner JP, Ehrensing RII, Kastin AJ et al. A double-blind, placebo-controlled, efficacy, safety and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression. J. Affect. Disord 61 (1–2), 119–126 (2000).
   Google Scholar
• Kelly JP, Nicolau G, Redmond A et al The effect of treatment with a new antidepressant, INN 00835, on platelet serotonin uptake in depressed patients. Disorcl 55(2–3), 231–235 (1999).
   Google Scholar
• Pekary AE, Meyerhoff JL, Sattin A. Electroconvulsive seizures modulate levels of thyrotropin releasing hormone and related peptides in rat hypothalamus, cingulate and lateral cerebellum. Brain Res. 884(1-2), 174–183 (2000).
   PubMedGoogle Scholar
• Lloyd RL, Pekary AE, Sattin A, Amundson T Antidepressant effects of thyrotropin-releasing hormone analogues using a rodent model of depression. Pharmacol Biochem. Behav. 70(1), 15–22 (2001).
   Google Scholar
• Uvnas-Moberg K, Bjokstrand E, Hillegaart V, Ahlenius S. Oxytocin as a possible mediator of SSRI-induced antidepressant effects. fiychopharmacology (Ben.) 142 (1), 95–101 (1999).
   Google Scholar
• Zhou JN, Riemersma RF, Unmehopa UA et al Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch. Gen. Psychiatry 58(7), 655–662 (2001).
   Google Scholar
• Van Londen L, Goekoop JG, Zwinderman AH, Lanser JB, Wiegant VM, De Wied D. Neuropsychological performance and plasma cortisol, arginine vasopressin and oxytocin in patients with major depression. Psychol. Merl 28(2), 275–284 (1998).
   Google Scholar
• Stogner KA, Holmes PV Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. j Pharmacol 387(2), R9–10 (2000).
   PubMed Web of Science ®Google Scholar
• Broqua PP, Wettstein JJ, Rocher MM, Gauthier-Martin BB, Junien JJ. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. &hay. Phalmacol 6(3), 215–222 (1995).
   Google Scholar
• Morgan CA, 3rd, Wang S, Southwick SM et al Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol. Psychiatry 47(10), 902–909 (2000).
   PubMed Web of Science ®Google Scholar
• Perez V, Puiigdemont D, Gilaberte I, Alvarez E, Artigas E Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic and methodologic factors. Clin. fiychophatmacol 21(1), 36–45 (2001).
   PubMedGoogle Scholar
• Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. Clin. Psychopharmacol 18(6), 441–446 (1998).
   PubMed Web of Science ®Google Scholar
• Pollock BG, Ferrell RE, Mulsant BH et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology23(5), 587–590 (2000).
   PubMed Web of Science ®Google Scholar
• Kim DK, Lim SW, Lee S et al Serotonin transporter gene polymorphism and antidepressant response. Neuromport 11(1), 215–219 (2000).
   PubMedGoogle Scholar
• Lesch KP, Bengel D, Hells A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292), 1527–1531 (1996).
   PubMed Web of Science ®Google Scholar
• Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. At& Gem Psychiatry 58(6), 539–544 (2001).
   PubMed Web of Science ®Google Scholar
• Russo-Neustadt A, Ha T, Ramirez R, Kesslak JR Physical activity-antidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model. fkhav. Brain Res. 120(1), 87–95 (2001).
   PubMed Web of Science ®Google Scholar
• Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Rychiatry 49(9), 741–752 (2001).
   Google Scholar
• Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry 48(8), 766–777 (2000).
   PubMed Web of Science ®Google Scholar
• Sheline YT. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol. Rychiatry48 (8), 791–800 (2000).
   Google Scholar
• Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276(34), 31674–31683 (2001).
   Google Scholar
• Chen G, Huang LD, Zeng WZ, H KM. Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability. int. J. Neuropsychopharmacol 4(1), 47–64 (2001).
   Google Scholar
• Kuldey M, Schaper C, Becker A, Rose K, Krieglstein J. Effect of 5-hydroxytryptamine 1A receptor agonist BAY X 3702 on BCL-2 and BAX proteins level in the ipsilateral cerebral cortex of rats after transient focal ischaemia. Neumscience 107(3), 405–413 (2001).
   Google Scholar
• Carvey PM, McGuire SO, Ling ZD. Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Relat. Disonl 7(3), 213–223 (2001).
   Google Scholar
• Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J. Gun. Psychopharmacol 17(3), 185–189 (1997).
   Google Scholar
• Berman RM, Cappiello A, Anand A et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47(4), 351–354 (2000).
   PubMed Web of Science ®Google Scholar
• McDonald BJ, Chung HJ, Huganir RL. Identification of protein kinase C phosphorylation sites within the AMPA receptor G1uR2 subunit. Neurophalmacology 41(6), 672–679 (2001). Affiliations
   Google Scholar